Your browser is no longer supported. Please, upgrade your browser.
MDGL [NASD]
Madrigal Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-14.65 Insider Own2.10% Shs Outstand16.64M Perf Week-9.86%
Market Cap1.08B Forward P/E- EPS next Y-14.22 Insider Trans0.00% Shs Float13.99M Perf Month-28.17%
Income-236.40M PEG- EPS next Q-3.87 Inst Own77.00% Short Float9.89% Perf Quarter-20.04%
Sales- P/S- EPS this Y-140.10% Inst Trans-5.54% Short Ratio8.39 Perf Half Y-30.57%
Book/sh14.12 P/B4.36 EPS next Y3.50% ROA-76.90% Target Price174.20 Perf Year-49.52%
Cash/sh17.05 P/C3.61 EPS next 5Y0.00% ROE-94.00% 52W Range58.29 - 142.62 Perf YTD-27.31%
Dividend- P/FCF- EPS past 5Y-62.80% ROI- 52W High-56.35% Beta1.26
Dividend %- Quick Ratio4.40 Sales past 5Y- Gross Margin- 52W Low6.80% ATR5.12
Employees42 Current Ratio4.40 Sales Q/Q- Oper. Margin- RSI (14)30.64 Volatility8.78% 7.18%
OptionableYes Debt/Eq0.00 EPS Q/Q-1.10% Profit Margin- Rel Volume0.26 Prev Close61.60
ShortableYes LT Debt/Eq0.00 EarningsNov 04 BMO Payout- Avg Volume164.98K Price62.25
Recom1.90 SMA20-18.47% SMA50-21.20% SMA200-33.00% Volume2,983 Change1.06%
Oct-07-21Initiated Jefferies Buy $151
Aug-06-21Upgrade BMO Capital Markets Market Perform → Outperform
May-20-21Resumed Goldman Buy $195
Nov-24-20Resumed Evercore ISI Outperform $180
Nov-06-20Reiterated H.C. Wainwright Buy $165 → $184
Jul-31-20Initiated Piper Sandler Overweight $208
Jun-05-20Initiated BMO Capital Markets Market Perform $135
May-05-20Initiated Chardan Capital Markets Buy $205
Jan-30-20Initiated Canaccord Genuity Buy $198
Jan-09-20Upgrade UBS Neutral → Buy $125 → $127
Nov-07-19Reiterated H.C. Wainwright Buy $225 → $215
Jun-25-19Initiated Stifel Hold
Jun-10-19Upgrade B. Riley FBR Neutral → Buy $128
Feb-28-19Reiterated H.C. Wainwright Buy $313 → $228
Feb-22-19Initiated SVB Leerink Outperform $165
Jan-23-19Initiated UBS Neutral $119
Dec-14-18Initiated Wolfe Research Outperform
Dec-12-18Initiated B. Riley FBR Neutral $124
Nov-19-18Downgrade Raymond James Mkt Perform → Underperform
Nov-16-18Upgrade Evercore ISI In-line → Outperform
Jan-10-22 08:00AM  
Jan-07-22 12:29PM  
Jan-04-22 06:26AM  
Dec-30-21 08:00AM  
Dec-22-21 09:16AM  
Nov-23-21 07:00AM  
Nov-20-21 08:45AM  
Nov-12-21 08:00AM  
Nov-04-21 06:50AM  
Oct-27-21 11:01AM  
Oct-18-21 12:12PM  
Oct-04-21 06:50AM  
Aug-09-21 09:44AM  
Aug-05-21 06:50AM  
Aug-02-21 06:50AM  
Jul-27-21 10:00AM  
Jul-26-21 03:27PM  
Jul-13-21 05:47PM  
Jun-30-21 06:50AM  
Jun-25-21 11:30AM  
Jun-08-21 06:50AM  
May-24-21 04:22AM  
May-21-21 09:38AM  
May-18-21 09:00AM  
06:50AM  
May-06-21 06:50AM  
Mar-18-21 12:22PM  
Feb-25-21 06:50AM  
Dec-16-20 10:36PM  
Nov-24-20 01:45AM  
Nov-13-20 06:50AM  
Nov-05-20 06:50AM  
Sep-03-20 06:50AM  
Sep-02-20 11:20AM  
Aug-26-20 06:50AM  
Aug-06-20 06:50AM  
Jun-27-20 10:19PM  
Jun-17-20 07:10PM  
Jun-15-20 05:19PM  
03:56PM  
Jun-06-20 12:29PM  
May-28-20 08:07AM  
May-14-20 05:31PM  
May-10-20 03:18PM  
May-07-20 06:50AM  
May-05-20 11:00AM  
Apr-14-20 06:50AM  
Mar-30-20 06:06PM  
Feb-28-20 10:49AM  
Feb-26-20 06:50AM  
Feb-05-20 04:11PM  
Jan-21-20 01:27PM  
Dec-19-19 07:28PM  
Dec-18-19 06:50AM  
Dec-13-19 06:20AM  
Dec-10-19 11:58PM  
04:01PM  
Nov-29-19 08:41AM  
Nov-11-19 05:30PM  
Nov-06-19 06:50AM  
Oct-26-19 01:22PM  
Sep-19-19 03:28PM  
Aug-07-19 06:50AM  
Jul-11-19 06:50AM  
Jul-10-19 01:26PM  
Jul-02-19 06:50AM  
Jun-19-19 09:07PM  
Jun-07-19 01:29PM  
Jun-04-19 06:50AM  
May-15-19 04:42PM  
May-08-19 10:14AM  
06:56AM  
06:50AM  
May-01-19 12:49PM  
Apr-08-19 06:50AM  
Apr-06-19 08:03AM  
Mar-28-19 06:50AM  
Mar-01-19 11:49AM  
Feb-27-19 01:25PM  
10:39AM  
06:50AM  
Feb-20-19 08:11AM  
Feb-17-19 02:03PM  
Feb-12-19 04:20PM  
Jan-11-19 08:59AM  
Jan-08-19 05:13PM  
Dec-28-18 04:52PM  
Dec-12-18 11:03PM  
08:19AM  
Dec-08-18 03:03PM  
Nov-28-18 08:40AM  
Nov-23-18 09:15PM  
Nov-19-18 08:15PM  
02:57PM  
Nov-14-18 08:31AM  
Nov-12-18 03:37PM  
11:30AM  
09:00AM  
Nov-06-18 06:50AM  
Oct-27-18 07:18AM  
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is MGL-3196, a liver-directed selective thyroid hormone receptor- agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.